It's official: the holiday season is here, marking the beginning of the race to the end of the year. It's also time for another FOMC interest rate decision, as well as for another look at the employment situation, perhaps the most dreaded measure of the economic recovery in the U.S. This week will bring the Challenger job cut announcements for October on Wednesday, initial jobless claims for last week and the Monster Employment Index for October on Thursday, and the employment numbers for October on Friday.

The earnings season rolls on this week as well, and analysts surveyed by Thomson Reuters are expecting good showings from the reports of Boston Beer Company Inc. (NYSE: SAM), DirecTV Group Inc. (NASDAQ: DTV), Sara Lee Corp. (NYSE: SLE), Starbucks Corp. (NASDAQ: SBUX), and Whole Foods Market Inc. (NASDAQ: WFMI).

"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

The Cabot Benjamin Graham Value Letter focuses on stocks that meet the strict value criteria of the legendary investor. Here, J. Royden Ward looks to Teva Pharmaceutical (NASDAQ: TEVA), noting, "Teva is based in Israel and develops, makes and sells generic and proprietary-branded (store brand) drugs."

The advisor explains, "The company is one of the largest generic drug-producing companies in the world and, in addition, sells active ingredients to other pharmaceutical companies.

"Teva's aggressive acquisition and product development programs are driving strong sales growth. The company recently purchased U.S.-based Barr Pharmaceuticals for $7.5 billion. Barr will increase Teva's generic drug sales significantly in the U.S. and parts of Europe.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide.

The long-term chart shows a stock that has never been in a bear market.

The recent resistance line is merely a pause in its long-term upward march, and it was broken by heavy buying in April. Teva ran to a new all-time high above $55, and then pulled back on profit-taking.

If you're looking for the most accurate way to predict the direction a stock or the market is headed, technical analysis is it.

Of course, no chart pattern is accurate all of the time (which is why technical analysis is more of an art than a science), but it's the closest you're going to get to a sure thing in the stock market.

So I'm offering up six technical trades today. Each of these stocks' charts are giving off extremely bullish signals and look ready to run higher.

One of the complaints we often hear is that the private insurance companies are gouging customers, second guessing doctors, and cutting corners at every turn to increase profit margins. A great deal of this is true and I would not debate that this dilutes the quality of health care in the United States.

Is the corollary that the government intends to run a health care program that does not make a profit?

That is a very probable outcome. If that is the case then how is it possible that the government will be able to fund something that is a money loser from the get go?

U.S. stock futures declined Tuesday morning after managing to close higher on Monday to extend the remarkable rally in the markets in the last two weeks. Today, more earnings are on tap, and investors will also focus on housing data coming out before the opening bell. Finally, there is a hearing about the energy trading that would be of interest to investors.

What on many investors' minds these past recent days is how long will the rally continue. The market, on Monday, on the one hand showed resilience following some disappointing earnings and pressures from sellers trying to cash in profits. On the other hand, the surprise climb in housing sales perhaps should have triggered a more convincing positive performance. While no doubt some would want to take some profit of the table in the coming days, more positive news from corporate results to economic data indicating a better third quarter could sustain markets.

"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

Surviving this recession is foremost on peoples' minds, but giving to charity is especially important in times like these. So how can you effectively give while preserving your net worth?

If you plan on liquidating any profitable, or taxable, positions in the stock market thanks to the current uptrend and also want to give to your favorite charity, the strategy outlined below is key to optimizing your gift, as well as your capital.

Though giving cash to causes is the most popular form of charity, desperate times call for creative measures, and any type of gift will be gladly accepted. By giving stock directly to charity, and bear in mind that the stock must be in your portfolio for one year or more as short-term capital gains are not applicable, you not only avoid capital gains taxes on your gains, but you can actually use the gift of your stock as a tax deduction. Hence, the cost of your gift is lower than giving cash directly. Think of it as an overall investment for yourself and the charity.

"Generic drug mak Teva Pharmaceutical, Ltd. (NASDAQ: TEVA) delivered respectable earnings results," says Jack Adamo, who added the stock his Insiders Plus model portfolio.

"The company's earnings were up 4% on a proforma non-GAAP basis. In this case, that's the correct measurement. Net GAAP earnings were up tremendously, but aren't really representative of normal business factors.

"Although Teva gets much of its earnings from its proprietary multiple sclerosis drug, Copaxone, its primary business is generic drugs. That segment is inherently lumpy because profitability is greatly affected by which generic drugs it brings to market before any other generic company.

Analyst upgrades:

• Jefferies upgraded Brocade (NASDAQ: BRCD) to Buy from Hold on expectations expanding OEM partnerships, new products and entry into new markets will drive long-term growth. The firm's channel checks indicate the first phase of an IBM (NYSE: IBM) deal for ethernet products will be announced next week. Jefferies raised its target price on the stock to $6 from $3.50.
  
• JMP Securities upgraded Broadcom (NASDAQ: BRCM) to Market Perform from Underperform citing the potential settlement with Qualcomm (NASDAQ: QCOM). The firm said Broadcom has far more to gain than Qualcomm has to lose.
  
• Citigroup upgraded Air Products (NYSE: APD) and Praxair (NYSE: PX) to Buy from Hold on expectations that an improvement in customer operating rates will benefit gas companies. The firm raised its target price on Air Products to $70 from $55 and on Praxair to $79 from $63.
  
• Royal Bank of Scotland upgraded BP Plc (NYSE: BP) to Buy from Hold to reflect its dividend yield at current levels.
• Apple (NASDAQ: AAPL) was raised to Outperform from Underperform at RBC Capital.
  
• T. Rowe Price (NYSE: TROW) was upgraded at Sandler O'Neill to Hold from Sell.
  
• Morgan Stanley (NYSE: MS) was lifted to Neutral from Underperform at Banc of America/Merrill.

Analyst upgrades:

• Bernstein upgraded Merck (NYSE: MRK) to Outperform from Market Perform and raised its target to $30 from $27 citing valuation and its decision to buy Schering-Plough, at what appears to be a reasonable price.
  
• RBC Capital upgraded Palm (NASDAQ: PALM) to Outperform from Sector Perform and raised its target to $12 from $5 as it believes webOS has increased its chances for Smartphone leadership and will increase its attractiveness as an acquisition target.
  
• RW Baird upgraded Alcatel-Lucent (NYSE: ALU) to Outperform from Neutral on valuation as it believes balance sheet risks are overly discounted in the stock, creating a buying opportunity. The firm has a $3 target on shares.
• Express Scripts (NASDAQ: ESRX) was raised to Buy from Hold at Argus.
  
• France Telecom (NYSE: FTE) was upgraded at Morgan Stanley to Equal Weight from Underweight.
  
• Foster Wheeler (NASDAQ: FWLT) was upgraded to Conviction Buy from Neutral at Goldman.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Apollo Group Inc. (NASDAQ: APOL) reported that Q4 revenue soared despite the recession.
• Baidu Inc. (NASDAQ: BIDU) posted strong annual revenue, but at a slowing growth rate.
• Career Education Corp. (NASDAQ: CECO) easily topped Q4 earnings expectations, lifting shares up.
• Comcast Corp. (NASDAQ: CMCSA) Q4 earnings beat expectations and it increased its dividend.
• CVS Caremark Corp. (NYSE: CVS) shares jumped after it reported higher earnings in Q4.
• Digital River Inc. (NASDAQ: DRIV) shares soared on better-than-expected Q4 earnings and revenue.
• Expedia Inc. (NASDAQ: EXPE) reported dismal results due to a huge good will write down.
• Goodyear Tire & Rubber Co. (NYSE: GT) posted a greater-than-expected Q4 net loss and announced job cuts.
• Hormel Foods Corp. (NYSE: HRL) exceeded Q1 earnings expectations due to the popularity of SPAM.

U.S. stock markets were set to plunge at the open Tuesday morning as three issues weighed on investors' minds: The economic stimulus plan, the auto industry as well as hard-hit Eastern Europe: Before the bell: Stocks set to plunge on stimulus package, auto sector worries

General Motors Corp. (NYSE: GM) and Chrysler LLC are expected to submit recovery plans to the government today to show how they can repay billions in loans and become viable. Of course, abysmal auto sales haven't been helping any company in the industry. Ex-Lazard banker Ron Bloom is expected to be named a key government adviser, according to The Wall Street Journal, and he is expected to be tough, demanding sacrifices by all involved, from auto workers and industry executives to shareholders and creditors. The AP reports that GM was making progress in concession talks with debtholders and the UAW. Also, GM Europe is considering shutting or selling as many as four European plants. GM shares are down 5.6% in premarket trading. GM shares declined over 12% an hour after the open.

Teva Pharmaceuticals (NASDAQ: TEVA - option chain) shares have moved higher today after the Food & Drug Administration approved the company's generic version Pulmicort, an asthma drug made by competitor AstraZeneca (NYSE: AZN). If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on TEVA.

TEVA opened this morning at $43.00. So far today the stock has hit a low of $42.55 and a high of $43.78. As of 12:25, TEVA is trading at $42.84, up $0.65 (1.5%). The chart for TEVA looks bullish and S&P gives TEVA a positive 5 STARS (out of 5) strong buy ranking.

For a bullish hedged play on this stock, I would consider a January bull-put credit spread below the $35 range.